Cisplatin SR is under clinical development by Eleison Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Cisplatin SR’s likelihood of approval (LoA) and phase transition for Osteosarcoma took place on 18 Feb 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Cisplatin SR Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Cisplatin SR overview

Cisplatin (inhaled lipid-complexed cisplatin (ILC)) is under development for the treatment of pediatric osteosarcoma and non-small cell lung cancer. It is administered through the inhalational route. It is a nano scale lipid-based complex sustained-release formulation of cisplatin. It acts by targeting DNA synthesis. The drug complex is based on sustained release lipid inhalation targeting (SLIT) technology. It was also under development for the treatment of ovarian cancer.

Eleison Pharmaceuticals overview

Eleison Pharmaceuticals is a drug development company that acquires, develops, and commercializes clinical stage drug candidates for orphan cancers. The company’s pipeline products include glufosfamide and inhaled lipid-complexed cisplatin. Its glufosfamide is an analog of chemotherapeutic agent for treatment of metabolically active tumors and hypoxic tumor regions. Eleison Pharmaceuticals’ inhaled lipid-complexed cisplatin is a sustained release formulation of cisplatin in a nanoscale lipid based complex used for pediatric osteosarcoma – bone cancer. The company provides clinical trials for pancreatic cancer and osteosarcoma. Eleison Pharmaceuticals is headquartered in Princeton, New Jersey, the US.

Quick View Cisplatin SR LOA Data

Report Segments
  • Innovator
Drug Name
  • Cisplatin SR
Administration Pathway
  • Inhalational
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.